Company profile for HanchorBio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

HanchorBio is dedicated to developing biological medicines with simultaneous multi-targeting through its novel IgG Fc-Based Designer Biologics (FBDB™) platform. With a culture rooted in innovation, quality, and speed, our vision is to be a pioneering biotech company transforming drug development with novel biologic modalities. Our mission is to transcend immuno-oncology therapeutics by creating cutting-edge designer biologic...
HanchorBio is dedicated to developing biological medicines with simultaneous multi-targeting through its novel IgG Fc-Based Designer Biologics (FBDB™) platform. With a culture rooted in innovation, quality, and speed, our vision is to be a pioneering biotech company transforming drug development with novel biologic modalities. Our mission is to transcend immuno-oncology therapeutics by creating cutting-edge designer biologics with innovative modalities to improve the lives of cancer patients worldwide.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Taiwan
Address
Address
5F, No. 1, Sec. 1, Tiding Blvd., Neihu Dist., Taipei City 114
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Natural Product Expo West

Natural Product Expo West

Not Confirmed

envelop Contact Supplier

Natural Product Expo West

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/hanchorbio-receives-fda-orphan-drug-designation-for-hcb101-in-gastric-cancer-302687341.html

PR NEWSWIRE
13 Feb 2026

https://www.prnewswire.com/news-releases/hanchorbio-and-wuxi-biologics-enter-strategic-partnership-to-advance-next-generation-bi-and-multi-functional-fusion-protein-pipeline-302669807.html

PR NEWSWIRE BIO
26 Jan 2026

https://www.prnewswire.com/news-releases/hanchorbio-announces-oral-presentation-of-hcb101-at-the-esmo-immuno-oncology-congress-2025-302637764.html

PR NEWSWIRE
11 Dec 2025

https://www.prnewswire.com/news-releases/hanchorbio-presents-two-late-breaking-abstracts-at-the-society-for-immunotherapy-of-cancer-2025-demonstrating-best-in-class-potential-of-hcb101-in-advanced-cancers-302606530.html

PR NEWSWIRE
07 Nov 2025

https://www.prnewswire.com/news-releases/hanchorbio-presents-preclinical-data-on-hcb301-at-sitc-2025-302604990.html

PR NEWSWIRE
05 Nov 2025

https://www.prnewswire.com/news-releases/hanchorbio-presents-phase-1-hcb101-clinical-results-at-faco-2025-demonstrating-safety-and-early-antitumor-activity-302592955.html

PR NEWSWIRE
24 Oct 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty